Davidowitz EJ, Krishnamurthy PK, Lopez P, Jimenez H, Adrien L, Davies P, Moe JG (2020). In Vivo Validation of Small Molecule Inhibitor of Tau Self-Association in htau Mice. Journal of Alz, vol. 73, no. 1, pp. 147-161, 2020.
Fá M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, Li Puma DD, Chatterjee I, Li J, Saeed F, Berman HL, Ripoli C, Gulisano W, Gonzalez J, Tian H, Costa JA, Lopez P, Davidowitz E, Yu WH, Haroutunian V, Brown LM, Palmeri A, Sigurdsson EM, Duff KE, Teich AF, Honig LS, Sierks M, Moe JG, D’Adamio L, Grassi C, Kanaan NM, Fraser PE, Arancio O. (2016) Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Sci Rep 6, 19393.
Tian H, Davidowitz E, Lopez P, He P, Schulz P, Moe J, Sierks MR (2015). Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiol Aging 36, 1342-55.
Tian H, Davidowitz E, Lopez P, Emadi S, Moe J, Sierks M (2013) Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int J Cell Biol. 2013:260787.
Davidowitz EJ, Chatterjee I, Moe JG (2008) Targeting tau oligomers for therapeutic development for Alzheimer’s disease and tauopathies. Curr Topics Biotechnol 4, 47-64.
Moe, James G. et al. CNS drug-like inhibitors of tau oligomerization. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2017, Volume 13, Issue 7, P1580.
Moe, James G. et al. Small molecule tau oligomerization inhibitors. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2016, Volume 12, Issue 7, P434.
Krishnamurthy, Pavan K. et al. Characterization of tool compounds targeting tau oligomers. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2015, Volume 11, Issue 7, P906.
Moe, James G. et al. Drug development of inhibitors of tau oligomer formation for Alzheimer’s disease and tauopathies. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2014, Volume 10, Issue 4, P865 – P866.
Moe, James et al. Small-molecule lead identification for inhibition of tau oligomer formation. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2013, Volume 9, Issue 4, P891.
Davidowitz, Eliot et al. Characterization of a novel monoclonal antibody specific for a tau autoproteolytic cut site that differentiates between Alzheimer’s disease and non-Alzheimer’s specimens. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2013, Volume 9, Issue 4, P308.
Moe, James G. et al. Extracellular oligomeric tau inhibits memory formation in mice. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2010, Volume 6, Issue 4, S277.
Moe, James G. et al. Modulation of synaptic function by extracellular tau enriched in oligomers. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2009, Volume 5, Issue 4 , P499.
Fá M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, Li Puma DD, Chatterjee I, Li J, Saeed F, Berman HL, Ripoli C, Gulisano W, Gonzalez J, Tian H, Costa JA, Lopez P, Davidowitz E, Yu WH, Haroutunian V, Brown LM, Palmeri A, Sigurdsson EM, Duff KE, Teich AF, Honig LS, Sierks M, Moe JG, D’Adamio L, Grassi C, Kanaan NM, Fraser PE, Arancio O. (2016) Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Sci Rep 6, 19393.
Tian H, Davidowitz E, Lopez P, He P, Schulz P, Moe J, Sierks MR (2015). Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiol Aging 36, 1342-55.
Tian H, Davidowitz E, Lopez P, Emadi S, Moe J, Sierks M (2013) Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int J Cell Biol. 2013:260787.
Davidowitz EJ, Chatterjee I, Moe JG (2008) Targeting tau oligomers for therapeutic development for Alzheimer’s disease and tauopathies. Curr Topics Biotechnol 4, 47-64.
Abstracts
Moe, James G. et al. In vivo efficacy of a small molecule inhibitor of tau oligomer formation in htau mice. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2018, Volume 14, Issue 7, P1527 – P1528.Moe, James G. et al. CNS drug-like inhibitors of tau oligomerization. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2017, Volume 13, Issue 7, P1580.
Moe, James G. et al. Small molecule tau oligomerization inhibitors. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2016, Volume 12, Issue 7, P434.
Krishnamurthy, Pavan K. et al. Characterization of tool compounds targeting tau oligomers. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2015, Volume 11, Issue 7, P906.
Moe, James G. et al. Drug development of inhibitors of tau oligomer formation for Alzheimer’s disease and tauopathies. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2014, Volume 10, Issue 4, P865 – P866.
Moe, James et al. Small-molecule lead identification for inhibition of tau oligomer formation. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2013, Volume 9, Issue 4, P891.
Davidowitz, Eliot et al. Characterization of a novel monoclonal antibody specific for a tau autoproteolytic cut site that differentiates between Alzheimer’s disease and non-Alzheimer’s specimens. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2013, Volume 9, Issue 4, P308.
Moe, James G. et al. Extracellular oligomeric tau inhibits memory formation in mice. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2010, Volume 6, Issue 4, S277.
Moe, James G. et al. Modulation of synaptic function by extracellular tau enriched in oligomers. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2009, Volume 5, Issue 4 , P499.
Coming Soon!
